Postpartum Depression Treatment Guidelines

Initial Assessment and Treatment

The American Academy of Family Physicians recommends sertraline as the first-line antidepressant for breastfeeding women with postpartum depression, starting at 25-50 mg daily, due to its minimal passage into breast milk and decades of safety data 1, 2
The American Academy of Family Physicians suggests checking thyroid function, as postpartum thyroiditis affects 5-7% of women in the first year after delivery and symptoms overlap substantially with depression 3, 4
The American Academy of Family Physicians recommends assessing for anemia, as it is common postpartum and contributes to fatigue and mood symptoms 3
The American College of Obstetricians and Gynecologists recommends evaluating severity using the Edinburgh Postnatal Depression Scale, with scores ≥10 indicating possible depression requiring treatment, and 95% sensitivity and 93% specificity 5, 6

For moderate to severe depression, the American Academy of Family Physicians recommends starting sertraline at 25-50 mg daily, as it is the preferred SSRI regardless of breastfeeding status 1, 2, 5, 6
The American Academy of Family Physicians suggests combining sertraline with cognitive behavioral therapy for optimal outcomes in moderate to severe depression 6

The American Academy of Family Physicians recommends paroxetine as an alternative, as it has minimal breast milk transfer 1, 2
The American Academy of Family Physicians suggests considering other SSRIs, such as fluoxetine, citalopram, and escitalopram, as they are considered compatible with breastfeeding, although with slightly higher milk transfer than sertraline 1

The American Academy of Family Physicians recommends continuing treatment for 4-12 months minimum for a first episode of major depression, and extending treatment duration indefinitely for women with recurrent depression or multiple prior episodes 1, 2
The American College of Obstetricians and Gynecologists suggests scheduling reassessment at 2-4 weeks after initiation to evaluate response and side effects 5, 6

The American Academy of Family Physicians recommends screening for suicidal ideation at every visit, as the risk is highest in the first few months of treatment or with dose changes 7

Systematic reviews of clinical studies report that hormone replacement therapy (HRT) has not demonstrated any clinical benefit for treating postpartum depression, and hormone levels measured in the postpartum period do not predict treatment response. Consequently, HRT is not recommended as a primary therapeutic option for postpartum depression in breastfeeding women. 8, 9

The landmark Bloch study showed that women with a prior history of postpartum depression are uniquely sensitive to hormonal fluctuations; however, there was no correlation between circulating estradiol or progesterone concentrations and depression severity scores. This indicates that simply replacing hormones does not address the underlying vulnerability that drives postpartum depressive episodes. 8, 9